Close
Athos Therapeutics, a pioneer in AI-based small molecule therapeutics, has partnered with Vultr, a cloud computing platform, to run its AI model training, tuning, and inference. Athos aims to accelerate the development of precision therapeutics for patients with immune-mediated diseases and cancer by leveraging their autonomous AI analytical platform.
Led by experts in the field, including the founders of Kite Pharma and the discoverer of the miR-124 drug target, Athos is at the forefront of using AI and machine learning for precision medicine. By selecting Vultr's cloud GPU platform, Athos gains access to scalable, secure, and compliant infrastructure to train their AI algorithms effectively.
Business Insider on MSN.com 12month
Business Insider India 11month
YAHOO!Finance 14month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
